These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34295421)

  • 1. Minimal clinically important difference in idiopathic pulmonary fibrosis.
    Kang M; Marts L; Kempker JA; Veeraraghavan S
    Breathe (Sheff); 2021 Jun; 17(2):200345. PubMed ID: 34295421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.
    Nathan SD; du Bois RM; Albera C; Bradford WZ; Costabel U; Kartashov A; Noble PW; Sahn SA; Valeyre D; Weycker D; King TE
    Respir Med; 2015 Jul; 109(7):914-22. PubMed ID: 25956020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical activity in idiopathic pulmonary fibrosis: Longitudinal change and minimal clinically important difference.
    Shingai K; Matsuda T; Kondoh Y; Kimura T; Kataoka K; Yokoyama T; Yamano Y; Ogawa T; Watanabe F; Hirasawa J; Reid WD; Kozu R
    Chron Respir Dis; 2023; 20():14799731231221818. PubMed ID: 38108832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Improvement and Effectiveness of Exercise-Based Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis: A BRIEF ANALYTICAL REVIEW.
    Vainshelboim B
    J Cardiopulm Rehabil Prev; 2021 Jan; 41(1):52-57. PubMed ID: 33186196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal Clinically Important Difference (MCID) in Patient-Reported Outcome Measures for Neurological Conditions: Review of Concept and Methods.
    Mishra B; Sudheer P; Agarwal A; Srivastava MVP; Nilima ; Vishnu VY
    Ann Indian Acad Neurol; 2023; 26(4):334-343. PubMed ID: 37970301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis.
    Kang M; Veeraraghavan S; Martin GS; Kempker JA
    ERJ Open Res; 2021 Oct; 7(4):. PubMed ID: 34671666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.
    du Bois RM; Weycker D; Albera C; Bradford WZ; Costabel U; Kartashov A; King TE; Lancaster L; Noble PW; Sahn SA; Thomeer M; Valeyre D; Wells AU
    Am J Respir Crit Care Med; 2011 Dec; 184(12):1382-9. PubMed ID: 21940789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
    Katano T; Sekine A; Ikeda S; Yamakawa H; Misumi T; Okabayashi H; Okuda R; Kitamura H; Baba T; Komatsu S; Hagiwara E; Ogura T
    Respir Investig; 2021 Jul; 59(4):414-420. PubMed ID: 33618993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib for Idiopathic Pulmonary Fibrosis.
    Tepede A; Yogaratnam D
    J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
    Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
    Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
    [No Abstract]   [Full Text] [Related]  

  • 17. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study.
    Cameli P; Refini RM; Bergantini L; d'Alessandro M; Alonzi V; Magnoni C; Rottoli P; Sestini P; Bargagli E
    Front Mol Biosci; 2020; 7():581828. PubMed ID: 33102528
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.